Bioactive Lipids, LPC and LPA, Are Novel Prometastatic Factors and Their Tissue Levels Increase in Response to Radio/Chemotherapy

Bioactive lipids are fundamental mediators of a number of critical biologic processes such as inflammation, proliferation, and apoptosis. Rhabdomyosarcoma (RMS) is common in adolescence with histologic subtypes that favor metastasis. However, the factors that influence metastasis are not well appreciated. Here, it is shown that lysophosphatidylcholine (LPC) and its derivative, lysophosphatidic acid (LPA), strongly enhance motility and adhesion of human RMS cells. Importantly, these metastatic-associated phenotypes were observed at physiologic concentrations of these lipids, which naturally occur in biologic fluids. Moreover, the effects of these bioactive lipids were much stronger as compared with known peptide-based prometastatic factors in RMS, such as stromal-derived factor-1 or hepatocyte growth factor/scatter factor. Finally, both LPC and LPA levels were increased in several organs after γ-irradiation or chemotherapy, supporting the hypothesis that radio/chemotherapy induces an unwanted prometastatic environment in these organs. Implications: LPC and LPA play a previously underappreciated role in dissemination of RMS and suggest that antimetastatic treatment with specific molecules blocking LPC/LPA activity should be part of standard radio/chemotherapy arsenal. Mol Cancer Res; 12(11); 1560–73. ©2014 AACR.

[1]  M. Ratajczak,et al.  Induction of a tumor-metastasis-receptive microenvironment as an unwanted and underestimated side effect of treatment by chemotherapy or radiotherapy , 2013, Journal of Ovarian Research.

[2]  Mark J. Bowser,et al.  The paternally imprinted DLK1-GTL2 locus is differentially methylated in embryonal and alveolar rhabdomyosarcomas , 2013, International journal of oncology.

[3]  B. Brors,et al.  Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. , 2013, Experimental hematology.

[4]  P. Houghton,et al.  Bioactive Lipids S1P and C1P Are Prometastatic Factors in Human Rhabdomyosarcoma, and Their Tissue Levels Increase in Response to Radio/Chemotherapy , 2013, Molecular Cancer Research.

[5]  M. Ratajczak,et al.  Ceramide‐1‐Phosphate Regulates Migration of Multipotent Stromal Cells and Endothelial Progenitor Cells—Implications for Tissue Regeneration , 2013, Stem cells.

[6]  Zhi-wei Feng,et al.  Neural cell adhesion molecule modulates mesenchymal stromal cell migration via activation of MAPK/ERK signaling. , 2012, Experimental cell research.

[7]  C. Parish,et al.  Upregulation of heparanase in high-glucose-treated endothelial cells promotes endothelial cell migration and proliferation and correlates with Akt and extracellular-signal-regulated kinase phosphorylation , 2012, Molecular vision.

[8]  D. Im,et al.  Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo , 2012, Cancer science.

[9]  E. Blalock,et al.  Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. , 2012, Molecular endocrinology.

[10]  Shiaw-Min Hwang,et al.  Lysophosphatidic Acid Induces Erythropoiesis through Activating Lysophosphatidic Acid Receptor 3 , 2011, Stem cells.

[11]  Albert Zlotnik,et al.  Homeostatic chemokine receptors and organ-specific metastasis , 2011, Nature Reviews Immunology.

[12]  Tao Wu,et al.  Binding of Autotaxin to Integrins Localizes Lysophosphatidic Acid Production to Platelets and Mammalian Cells* , 2011, The Journal of Biological Chemistry.

[13]  M. Ratajczak,et al.  CONDITIONING FOR HEMATOPOIETIC TRANSPLANTATION ACTIVATES THE COMPLEMENT CASCADE AND INDUCES A PROTEOLYTIC ENVIRONMENT IN BONE MARROW – A NOVEL ROLE FOR BIOACTIVE LIPIDS AND SOLUBLE C5b-C9 AS HOMING FACTORS , 2011, Leukemia.

[14]  L. Schang,et al.  Lysophosphatidate Induces Chemo-Resistance by Releasing Breast Cancer Cells from Taxol-Induced Mitotic Arrest , 2011, PloS one.

[15]  P. Houghton,et al.  National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing , 2011, Pediatric blood & cancer.

[16]  M. Ratajczak,et al.  Overlapping and distinct role of CXCR7‐SDF‐1/ITAC and CXCR4‐SDF‐1 axes in regulating metastatic behavior of human rhabdomyosarcomas , 2010, International journal of cancer.

[17]  Yuanda Song,et al.  Autotaxin: a protein with two faces. , 2010, Biochemical and biophysical research communications.

[18]  C. Silliman,et al.  Lysophosphatidylcholines activate G2A inducing G(αi)₋₁-/G(αq/)₁₁- Ca²(+) flux, G(βγ)-Hck activation and clathrin/β-arrestin-1/GRK6 recruitment in PMNs. , 2010, The Biochemical journal.

[19]  M. Ratajczak,et al.  Macrophage Migration Inhibitory Factor Is Secreted by Rhabdomyosarcoma Cells, Modulates Tumor Metastasis by Binding to CXCR4 and CXCR7 Receptors and Inhibits Recruitment of Cancer-Associated Fibroblasts , 2010, Molecular Cancer Research.

[20]  G. Prestwich,et al.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three‐dimensional lung cancer xenograft model , 2010, Cancer.

[21]  M. Ratajczak,et al.  PLASMA SPHINGOSINE 1-PHOSPHATE IS A MAJOR CHEMOATTRACTANT THAT DIRECTS EGRESS OF HEMATOPOIETIC STEM PROGENITOR CELLS FROM BONE MARROW AND ITS LEVEL IN PERIPHERAL BLOOD INCREASES DURING MOBILIZATION DUE TO ACTIVATION OF COMPLEMENT CASCADE/MEMBRANE ATTACK COMPLEX , 2010, Leukemia.

[22]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[23]  N. Samadi,et al.  Inhibition of autotaxin production or activity blocks lysophosphatidylcholine‐induced migration of human breast cancer and melanoma cells , 2009, Molecular carcinogenesis.

[24]  G. Ferry,et al.  S32826, A Nanomolar Inhibitor of Autotaxin: Discovery, Synthesis and Applications as a Pharmacological Tool , 2008, Journal of Pharmacology and Experimental Therapeutics.

[25]  A. Tucker,et al.  Lysophosphatidic acid (LPA) and angiogenesis , 2008, Angiogenesis.

[26]  N. Dhalla,et al.  Mechanisms of the lysophosphatidic acid-induced increase in [Ca2+]i in skeletal muscle cells , 2008, Journal of cellular and molecular medicine.

[27]  K. Kamata,et al.  Role of lysophosphatidylcholine (LPC) in atherosclerosis. , 2007, Current medicinal chemistry.

[28]  Feng Hao,et al.  Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha. , 2007, Biochimica et biophysica acta.

[29]  M. Jauhiainen,et al.  Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. , 2006, Biochemistry.

[30]  F. Huang,et al.  Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[31]  A. Abdel‐Mageed,et al.  Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. , 2005, Cancer research.

[32]  P. Houghton,et al.  Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. , 2003, Cancer research.

[33]  K. Fukuzawa,et al.  Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase* , 2002, The Journal of Biological Chemistry.

[34]  Oana A. Tomescu,et al.  CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. , 2002, Blood.

[35]  G. Mills,et al.  Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production , 2002, The Journal of cell biology.

[36]  N. Sugimoto,et al.  The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. , 2002, Journal of biochemistry.

[37]  A. Sandberg,et al.  Hematologic masquerade of rhabdomyosarcoma , 2001, American journal of hematology.

[38]  H. Koh,et al.  Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  H. Zhao,et al.  Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. , 2001, Medical and pediatric oncology.

[40]  Je‐ho Lee,et al.  17&bgr;-estradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism , 2001, Menopause.

[41]  G. Pei,et al.  Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. , 2000, Circulation research.

[42]  M. Obinata,et al.  Sphingosine-1-phosphate and lysophosphatidic acid trigger invasion of primitive hematopoietic cells into stromal cell layers. , 2000, Blood.

[43]  G. Mills,et al.  Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer , 2000, Annals of the New York Academy of Sciences.

[44]  K. Hirata,et al.  Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[45]  M. Miyazaki,et al.  Plasma human hepatocyte growth factor concentrations in patients with biliary obstruction , 2000, Journal of gastroenterology and hepatology.

[46]  Y. Nabeshima,et al.  Lysophosphatidic acid and bFGF control different modes in proliferating myoblasts , 1996, The Journal of cell biology.

[47]  L. Helman,et al.  In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. , 1994, Cancer research.

[48]  J. Biegel,et al.  Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. , 1994, Cancer research.

[49]  E. Kohn,et al.  Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[50]  M. Lagarde,et al.  Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. , 2000, The Biochemical journal.